Why It Matters

The House Energy and Commerce Committee's Health Subcommittee advanced three bills targeting counterfeit pill production on Wednesday, July 15, marking a bipartisan legislative push to combat the fentanyl crisis. The Trump administration has made drug trafficking enforcement a priority, and these bills align with that agenda by establishing new DEA oversight mechanisms for pill presses and enhanced criminal penalties for illicit manufacturers.

In 2025 alone, the Drug Enforcement Administration (DEA) seized more than 47 million fentanyl-laced counterfeit pills and nearly 10,000 pounds of fentanyl powder, a haul equivalent to more than 369 million lethal doses, since as little as 2 milligrams of fentanyl can kill. That math helps explain why the markup drew consensus: counterfeit pills laced with fentanyl continue to kill thousands of Americans every year, and lawmakers on both sides treated the pill-press supply chain as one of the few parts of the crisis Congress can act on directly.

The Big Picture

The three bills represent a coordinated legislative response to the growing sophistication of illicit drug operations. H.R. 7184, the PRESS Act, sponsored by Rep. Addison McDowell (R-NC), would direct the DEA to oversee a closed system of distribution for pill presses and their critical parts, similar to the system already used for controlled substances. They have additionally launched the Fentanyl Free America initiative, focused in part on ensuring DEA registrants are working within the closed system of distribution.

H.R. 5880, the Fight Illicit Pill Presses Act, sponsored by Reps. Harriet Hageman (R-WY) and Melanie Stansbury (D-NM), would require serial numbers on pill presses and their critical parts and impose recordkeeping and transaction-reporting requirements, with criminal penalties for removing or tampering with those numbers. 

H.R. 8005, the Stop Pills That Kill Act, sponsored by Rep. Gabe Evans (R-CO), would apply enhanced criminal penalties to those who illicitly manufacture fentanyl, fentanyl analogs, or fentanyl-related substances and would direct the DEA to establish a comprehensive plan addressing counterfeit pill production. A Senate companion to the Stop Pills That Kill Act, S. 3087, increases criminal penalties for offenses relating to the manufacture of fentanyl or counterfeit substances, signaling broader momentum on the issue.

The markup was a work session among committee members, with no external witnesses testifying. All three bills advanced to the Full Committee by voice vote, with H.R. 8005 forwarded as amended.

Political Stakes

For the Trump administration, these bills represent an opportunity to demonstrate action on a crisis that has devastated communities across the country. The fentanyl epidemic has become a defining domestic policy challenge, and legislation targeting the supply chain offers tangible progress on an issue with rare bipartisan support.

For committee members, the bills carry minimal political risk. Law enforcement endorsements provide political cover, and the legislation focuses on supply-side enforcement rather than contentious demand-reduction strategies.

Law enforcement groups have broadly backed the Fight Illicit Pill Presses Act. The National Narcotic Officers' Associations' Coalition, the National HIDTA Directors Association, the National Association of Police Organizations, the Major County Sheriffs of America, the Federal Law Enforcement Officers Association, the Sergeants Benevolent Association NYPD, and Community Anti-Drug Coalitions of America have all endorsed the bill's Senate companion.

The Bottom Line

All three bills joined a 29-bill Full Committee markup held July 20-21, alongside a wide range of energy and health care legislation. Given the bipartisan support and law enforcement backing, floor consideration in the House appears likely in the coming months. The Senate companion offers a vehicle for negotiations if the House passes its version, and the administration's emphasis on drug enforcement suggests the White House would welcome these bills reaching the president's desk.

Three bills targeting counterfeit pill production cleared subcommittee and moved directly into a broader Full Committee markup, reflecting rare bipartisan consensus on combating the fentanyl crisis through supply-chain enforcement and enhanced penalties for illicit manufacturers.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article